MedTrace Logo

Study of Gemtuzumab Ozogamicin Therapy in DNA Samples From Patients With Acute Myeloid Leukemia Treated on COG-AAML0531

NCT01407757 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2016-05-19

No results posted yet for this study

Summary

RATIONALE: DNA analysis of blood and tissue samples may help doctors predict how well patients will respond to treatment. It may also help doctors learn more about how gemtuzumab ozogamicin works in the body.

PURPOSE: This research study is looking at gemtuzumab ozogamicin in DNA samples from patients with acute myeloid leukemia treated on COG-AAML0531.

Conditions

Interventions

GENETIC

DNA analysis

GENETIC

gene expression analysis

OTHER

laboratory biomarker analysis

OTHER

pharmacogenomic studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Children's Oncology Group

    lead NETWORK

Principal Investigators

  • Jatinder Lamba, MD · Masonic Cancer Center, University of Minnesota

Eligibility

Max Age
29 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2016-05-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01407757 on ClinicalTrials.gov